Zevra Therapeutics Launches MIPLYFFA™ (arimoclomol) in the US for Niemann-Pick Disease Type C
Friday, November 22, 2024
Zevra Therapeutics has announced the commercial availability of MIPLYFFA™ (arimoclomol) in the United States.
MIPLYFFA works by activating transcription factors that upregulate lysosomal gene expression, which helps to reduce cholesterol build-up in NPC cells. Although the full clinical implications are not yet understood, a pivotal phase 3 trial demonstrated that MIPLYFFA slowed disease progression over one year compared to a placebo.
NPC is a rare, progressive disorder caused by genetic mutations that disrupt the transport of cholesterol and lipids within cells. This leads to harmful accumulations, particularly in neurons, resulting in significant neurological symptoms.
The condition affects both children and adults, with symptoms such as difficulties in speech, cognition, mobility, and swallowing. NPC is challenging to diagnose, often taking years, and its progression is irreversible, with serious implications for quality of life and life expectancy.
MIPLYFFA is the first therapy approved by the US Food and Drug Administration (FDA) for Niemann-Pick disease type C (NPC). It is intended for use alongside miglustat to address neurological symptoms in patients aged two years and older.
The treatment has received multiple FDA designations, including Breakthrough Therapy and Orphan Drug status, as well as recognition from the European Medicines Agency (EMA).
The launch of MIPLYFFA follows a shorter-than-anticipated timeline post-FDA approval. Zevra has been receiving prescription enrolments through its patient support programme, AmplifyAssist, which provides assistance to patients navigating insurance and funding processes.
AmplifyAssist offers comprehensive resources to help patients and caregivers manage their therapy. These include insurance guidance, financial support for eligible patients, information on disease management, and assistance with prescription refills. The service aims to reduce barriers and ensure timely access to medication. More details are available at MIPLYFFA.com or via a dedicated helpline.
Patients interested in starting treatment with MIPLYFFA are advised to consult their healthcare provider.
Source: globenewswire.com
